Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR
· Real-Time Price · USD
40.69
1.85 (4.76%)
At close: Sep 05, 2025, 11:29 AM
4.76% (1D)
| Bid | 38.5 |
| Market Cap | 251.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.77B |
| EPS (ttm) | -4.12 |
| PE Ratio (ttm) | -9.88 |
| Forward PE | -11.39 |
| Analyst | Buy |
| Ask | 41.35 |
| Volume | 12,565 |
| Avg. Volume (20D) | 43,567.5 |
| Open | 38.80 |
| Previous Close | 38.84 |
| Day's Range | 38.66 - 41.15 |
| 52-Week Range | 2.29 - 54.30 |
| Beta | 1.06 |
About MNPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MNPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MNPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+14.55%
Monopar Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago
+7%
Monopar Therapeutics shares are trading higher after the company announced it will join the Russell 3000 index.
19 hours ago · seekingalpha.com
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts ImminentMonopar Therapeutics Inc. is a clinical-stage biotech with two promising programs: ALXN1840 for Wilson disease and a radiopharmaceuticals pipeline targeting advanced cancers. ALXN1840 has shown superi...
